...
首页> 外文期刊>International journal of urology: official journal of the Japanese Urological Association >Recent trends in the treatment of testosterone deficiency syndrome.
【24h】

Recent trends in the treatment of testosterone deficiency syndrome.

机译:睾丸激素缺乏综合征治疗的最新趋势。

获取原文
获取原文并翻译 | 示例
           

摘要

Testosterone deficiency syndrome (TDS) is defined as a clinical and biochemical syndrome associated with advancing age and is characterized by typical symptoms and deficiency in serum testosterone levels. TDS is a result of the interaction of hypothalamo-pituitary and testicular factors. Now, treatment of TDS with testosterone is still controversial due to a lack of large, controlled clinical trials on efficacy. The risks of treatment with testosterone appear to be minimal, although long-term studies on the safety of testosterone therapy are lacking. The aim of the therapy is to establish a physiological concentration of serum testosterone in order to correct the androgen deficiency, relieve its symptoms and prevent long-term sequelae. All of the available products, despite their varying pharmacodynamic and pharmacokinetic profiles, are able to reach this goal. Newer testosterone patches seem not to cause severe skin irritation. Testosterone gels minimize the skin irritation while providing flexibilityin dosing and a low discontinuation rate. Oral testosterone undecanoate (TU) is free of liver toxicity. Recent formulation of oral TU markedly increased shelf-live, a major drawback in the older preparation. Producing swings in testosterone levels rising rapidly to the supraphysiological range is not the case with the new injectable long-acting preparation of TU. To be able to rapidly react and stop treatment in cases where side-effects and contraindications are detected, the short-acting transdermal and oral delivery modes have certain advantages. However, there is no evidence that the use of an injectable long-acting TU in men with TDS has limitations in clinical application for this reason. The use of dehydroepiandrosterone is still controversial because of a lack of well designed long-term trials, although some recent studies suggest positive effects on various body systems. Only a few studies have been carried out to investigate the effect of hCG (human chorionic gonadotropin) in TDS with some positive results on various body systems.
机译:睾丸激素缺乏综合症(TDS)被定义为与年龄增长有关的临床和生化综合症,其特征是典型症状和血清睾丸激素水平不足。 TDS是下丘脑-垂体和睾丸因子相互作用的结果。现在,由于缺乏关于疗效的大型对照临床试验,使用睾丸激素治疗TDS仍存在争议。尽管缺乏关于睾丸激素治疗安全性的长期研究,但使用睾丸激素治疗的风险似乎很小。该疗法的目的是确定血清睾丸激素的生理浓度,以纠正雄激素缺乏症,缓解其症状并预防长期后遗症。尽管具有不同的药效学和药代动力学特征,但所有可用的产品都能够实现这一目标。较新的睾丸激素贴剂似乎不会引起严重的皮肤刺激。睾丸激素凝胶剂可最大程度地减少皮肤刺激,同时提供给药灵活性和低中断率。口服十一酸睾丸酮(TU)无肝毒性。口服TU的最新制剂显着增加了保质期,这是较老制剂的主要缺点。新型可注射长效制剂TU的情况并非如此,导致睾丸激素水平快速上升至超生理范围的生产波动。为了在发现副作用和禁忌症时能够迅速反应并停止治疗,短效透皮和口服给药方式具有一定优势。然而,由于这一原因,没有证据表明在患有TDS的男性中使用可注射的长效TU在临床上存在局限性。由于缺乏精心设计的长期试验,脱氢表雄酮的使用仍存在争议,尽管最近的一些研究表明对多种人体系统有积极作用。仅进行了很少的研究来研究hCG(人绒毛膜促性腺激素)在TDS中的作用,并对各种身体系统产生一些积极的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号